

# Jan Beyersmann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4212066/publications.pdf>

Version: 2024-02-01

75  
papers

2,789  
citations

257450

24  
h-index

197818

49  
g-index

76  
all docs

76  
docs citations

76  
times ranked

3961  
citing authors

#	ARTICLE	IF	CITATIONS
1	A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 648-653.	5.0	339
2	Competing Risks and Multistate Models with R. , 2012, , .		214
3	The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: a multicentre retrospective cohort study. <i>Eurosurveillance</i> , 2016, 21, .	7.0	157
4	Simulating competing risks data in survival analysis. <i>Statistics in Medicine</i> , 2009, 28, 956-971.	1.6	151
5	Estimating the Cost of Health Care—Associated Infections: Mind Your p <sup>TM</sup> s and q <sup>TM</sup> s. <i>Clinical Infectious Diseases</i> , 2010, 50, 1017-1021.	5.8	146
6	An easy mathematical proof showed that time-dependent bias inevitably leads to biased effect estimation. <i>Journal of Clinical Epidemiology</i> , 2008, 61, 1216-1221.	5.0	145
7	Empirical Transition Matrix of Multi-State Models: The <code>etm</code> Package. <i>Journal of Statistical Software</i> , 2011, 38, .	3.7	116
8	Risk factors for the development of nosocomial pneumonia and mortality on intensive care units: application of competing risks models. <i>Critical Care</i> , 2008, 12, R44.	5.8	114
9	Time-dependent covariates in the proportional subdistribution hazards model for competing risks. <i>Biostatistics</i> , 2008, 9, 765-776.	1.5	102
10	Hospital-acquired infections—appropriate statistical treatment is urgently needed!. <i>International Journal of Epidemiology</i> , 2013, 42, 1502-1508.	1.9	85
11	Nosocomial Infection, Length of Stay, and Time-Dependent Bias. <i>Infection Control and Hospital Epidemiology</i> , 2009, 30, 273-276.	1.8	78
12	Understanding competing risks: a simulation point of view. <i>BMC Medical Research Methodology</i> , 2011, 11, 86.	3.1	77
13	The impact of time-dependent bias in proportional hazards modelling. <i>Statistics in Medicine</i> , 2008, 27, 6439-6454.	1.6	76
14	A competing risks analysis of bloodstream infection after stem cell transplantation using subdistribution hazards and cause-specific hazards. <i>Statistics in Medicine</i> , 2007, 26, 5360-5369.	1.6	72
15	Modeling the effect of time-dependent exposure on intensive care unit mortality. <i>Intensive Care Medicine</i> , 2009, 35, 826-832.	8.2	47
16	Application of multistate models in hospital epidemiology: Advances and challenges. <i>Biometrical Journal</i> , 2011, 53, 332-350.	1.0	47
17	Competing Risks and Multistate Models. <i>Clinical Cancer Research</i> , 2013, 19, 12-21.	7.0	47
18	Statistical issues in the analysis of adverse events in time-to-event data. <i>Pharmaceutical Statistics</i> , 2016, 15, 297-305.	1.3	47

#	ARTICLE	IF	CITATIONS
19	Outcomes of Hypothermia in Addition to Decompressive Hemicraniectomy in Treatment of Malignant Middle Cerebral Artery Stroke. <i>JAMA Neurology</i> , 2019, 76, 571.	9.0	47
20	Incidence Densities in a Competing Events Analysis. <i>American Journal of Epidemiology</i> , 2010, 172, 1077-1084.	3.4	38
21	On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies. <i>Pharmaceutical Statistics</i> , 2019, 18, 166-183.	1.3	38
22	Two Pitfalls in Survival Analyses of Time-Dependent Exposure: A Case Study in a Cohort of Oscar Nominees. <i>American Statistician</i> , 2010, 64, 205-211.	1.6	36
23	Simulation shows undesirable results for competing risks analysis with time-dependent covariates for clinical outcomes. <i>BMC Medical Research Methodology</i> , 2018, 18, 79.	3.1	32
24	A competing risks approach for nonparametric estimation of transition probabilities in a non-Markov illness-death model. <i>Lifetime Data Analysis</i> , 2014, 20, 495-513.	0.9	30
25	Estimating summary functionals in multistate models with an application to hospital infection data. <i>Computational Statistics</i> , 2011, 26, 181-197.	1.5	28
26	Exposure density sampling: Dynamic matching with respect to a time-dependent exposure. <i>Statistics in Medicine</i> , 2019, 38, 4390-4403.	1.6	26
27	Association of acute kidney injury and bleeding events with mortality after radial or femoral access in patients with acute coronary syndrome undergoing invasive management: secondary analysis of a randomized clinical trial. <i>European Heart Journal</i> , 2019, 40, 1226-1232.	2.2	26
28	Subdistribution hazard models for competing risks in discrete time. <i>Biostatistics</i> , 2020, 21, 449-466.	1.5	26
29	Competing risk bias was common in a prominent medical journal. <i>Journal of Clinical Epidemiology</i> , 2016, 80, 135-136.	5.0	24
30	Transmission-associated nosocomial infections: Prolongation of intensive care unit stay and risk factor analysis using multistate models. <i>American Journal of Infection Control</i> , 2008, 36, 98-103.	2.3	23
31	Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTE's STAT-Net. <i>Clinical Infectious Diseases</i> , 2018, 67, 1922-1931.	5.8	23
32	Assessing assumptions for statistical analyses in randomised clinical trials. <i>BMJ Evidence-Based Medicine</i> , 2019, 24, 185-189.	3.5	23
33	Assessment of assumptions of statistical analysis methods in randomised clinical trials: the what and how. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 121-126.	3.5	23
34	A Wild Bootstrap Approach for the Aalen's Johansen Estimator. <i>Biometrics</i> , 2018, 74, 977-985.	1.4	22
35	Incidence in ICU populations: how to measure and report it?. <i>Intensive Care Medicine</i> , 2014, 40, 871-876.	8.2	19
36	Treatment intensification using long-acting insulin – predictors of future basal insulin supported oral therapy in the DIVE registry. <i>BMC Endocrine Disorders</i> , 2015, 15, 54.	2.2	19

#	ARTICLE	IF	CITATIONS
37	Survival analysis for Adverse events with VarYing follow-up times (SAVVY): Rationale and statistical concept of a meta-analytic study. <i>Biometrical Journal</i> , 2021, 63, 650-670.	1.0	16
38	Joint modeling of progression-free and overall survival and computation of correlation measures. <i>Statistics in Medicine</i> , 2019, 38, 4270-4289.	1.6	13
39	The wild bootstrap for multivariate Nelson-Aalen estimators. <i>Lifetime Data Analysis</i> , 2019, 25, 97-127.	0.9	12
40	Estimating and comparing adverse event probabilities in the presence of varying follow-up times and competing events. <i>Pharmaceutical Statistics</i> , 2021, 20, 1125-1146.	1.3	12
41	Survival analysis for Adverse events with VarYing follow-up times (SAVVY) estimation of adverse event risks. <i>Trials</i> , 2021, 22, 420.	1.6	12
42	Determinants of weight change in patients on basal insulin treatment: an analysis of the DIVE registry. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000301.	2.8	10
43	Bootstrapping complex time-to-event data without individual patient data, with a view toward time-dependent exposures. <i>Statistics in Medicine</i> , 2019, 38, 3747-3763.	1.6	10
44	Meta-analysis for aggregated survival data with competing risks: a parametric approach using cumulative incidence functions. <i>Research Synthesis Methods</i> , 2016, 7, 282-293.	8.7	9
45	Time-to-event methodology improved statistical evaluation in register-based health services research. <i>Journal of Clinical Epidemiology</i> , 2017, 82, 103-111.	5.0	9
46	Understanding Mortality of Femoral Fractures Following Low-Impact Trauma in Persons With and Without Care Need. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 221-226.	2.5	7
47	Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2017, 58, 97-102.	5.0	7
48	Prediction accuracy and variable selection for penalized cause-specific hazards models. <i>Biometrical Journal</i> , 2018, 60, 288-306.	1.0	7
49	Stabilizing cumulative incidence estimation of pregnancy outcome with delayed entries. <i>Biometrical Journal</i> , 2019, 61, 1290-1302.	1.0	7
50	Multistate methodology improves risk assessment under time-varying drug intake—a new view on pregnancy outcomes following coumarin exposure. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 616-624.	1.9	7
51	Statistical inference for state occupation and transition probabilities in non-Markov multi-state models subject to both random left-truncation and right-censoring. <i>Econometrics and Statistics</i> , 2023, 25, 110-124.	0.8	7
52	Florence Nightingale, William Farr and Competing Risks. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2017, 180, 285-293.	1.1	6
53	Relapse- and Immunosuppression-Free Survival after Hematopoietic Stem Cell Transplantation: How Can We Assess Treatment Success for Complex Time-to-Event Endpoints?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 992-997.	2.0	6
54	Design aspects of COVID-19 treatment trials: Improving probability and time of favorable events. <i>Biometrical Journal</i> , 2021, , .	1.0	6

#	ARTICLE	IF	CITATIONS
55	Assessing Noninferiority in Treatment Trials for Severe Infectious Diseases: an Extension to the Entire Follow-Up Period Using a Cure-Death Multistate Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	5
56	Estimation of adjusted expected excess length of stay associated with ventilation-acquired pneumonia in intensive care: A multistate approach accounting for time-dependent mechanical ventilation. <i>Biometrical Journal</i> , 2018, 60, 1135-1150.	1.0	5
57	Long-term risk for end-stage kidney disease and death in a large population-based cohort. <i>Scientific Reports</i> , 2018, 8, 7729.	3.3	5
58	Competing-risk outcomes after hematopoietic stem cell transplantation from the perspective of time-dependent effects. <i>Haematologica</i> , 2018, 103, 1527-1534.	3.5	5
59	Five years' trajectories of functionality and pain in patients after hip or knee replacement and association with long-term patient survival. <i>Scientific Reports</i> , 2020, 10, 14388.	3.3	5
60	Modelling two cause-specific hazards of competing risks in one cumulative proportional odds model?. <i>Statistics in Medicine</i> , 2017, 36, 4353-4363.	1.6	4
61	Bayesian Phase II optimization for time-to-event data based on historical information. <i>Statistical Methods in Medical Research</i> , 2019, 28, 1272-1289.	1.5	4
62	Estimating cumulative incidence functions in competing risks data with dependent left-truncation. <i>Statistics in Medicine</i> , 2020, 39, 481-493.	1.6	4
63	Adverse event development in clinical oncology trials. <i>Lancet Oncology</i> , The, 2016, 17, e263-e264.	10.7	3
64	RE: "COMPARISON OF STATISTICAL APPROACHES FOR DEALING WITH IMMORTAL TIME BIAS IN DRUG EFFECTIVENESS STUDIES". <i>American Journal of Epidemiology</i> , 2016, 184, 856-858.	3.4	3
65	The Analysis of Adverse Events in Randomized Clinical Trials. , 2019, , 537-557.		3
66	Long-Term Mortality of Patients With Osteoarthritis After Joint Replacement: Prognostic Value of Preoperative and Postoperative Pain and Function. <i>Arthritis Care and Research</i> , 2023, 75, 869-875.	3.4	3
67	Trueness of full-arch IO scans estimated based on 3D translational and rotational deviations of single teeth" an in vitro study. <i>Clinical Oral Investigations</i> , 2021, 26, 3273.	3.0	3
68	Evolution of disability in spinocerebellar ataxias type 1, 2, 3, and 6. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 286-295.	3.7	3
69	A simulation approach for power calculation in large cohort studies based on multistate models. <i>Biometrical Journal</i> , 2018, 60, 671-686.	1.0	2
70	Multistate modeling of clinical hold in randomized clinical trials. <i>Pharmaceutical Statistics</i> , 2020, 19, 262-275.	1.3	2
71	Estimating Infection Incidence in Longitudinal Studies. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 617-617.	1.8	1
72	Psychosocial Risk and Health Behaviors as Predictors of Clinical Events in Patients Wait-Listed for a New Heart: Results from 7 Years of Follow-Up. <i>Life</i> , 2021, 11, 1438.	2.4	1

#	ARTICLE	IF	CITATIONS
73	The predictive distribution of the residual variability in the linear fixed effects model for clinical cross-over trials. Biometrical Journal, 2016, 58, 797-809.	1.0	0
74	Statistical models for complex data in clinical and epidemiological research. Biometrical Journal, 2020, 62, 528-531.	1.0	0
75	Motor learning might contribute to a therapeutic anterior shift of the habitual mandibular position An exploratory study. Journal of Oral Rehabilitation, 2021, 48, 891-900.	3.0	0